Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.489 GBX | -0.31% | -20.68% | -57.05% |
Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
Apr. 03 | FTSE 100 up thanks to US economic data | AN |
Sales 2022 | 49K 61.14K | Sales 2023 | 55K 68.62K | Capitalization | 17.33M 21.63M |
---|---|---|---|---|---|
Net income 2022 | -4M -4.99M | Net income 2023 | -5M -6.24M | EV / Sales 2022 | 237 x |
Net cash position 2022 | 4.57M 5.71M | Net cash position 2023 | 2.36M 2.94M | EV / Sales 2023 | 272 x |
P/E ratio 2022 |
-3.18
x | P/E ratio 2023 |
-3.18
x | Employees | 43 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.93% |
1 week | -20.45% | ||
Current month | -31.71% | ||
1 month | -37.78% | ||
3 months | -30.00% | ||
6 months | -56.92% | ||
Current year | -56.92% |
Managers | Title | Age | Since |
---|---|---|---|
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Chris Yates
BRD | Director/Board Member | 50 | 18-08-21 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 18-04-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 3.489 | -0.31% | 599 442 |
24-05-08 | 3.5 | -9.68% | 4,599,462 |
24-05-07 | 3.875 | -11.43% | 4,184,023 |
24-05-03 | 4.375 | -0.57% | 2,228,811 |
24-05-02 | 4.4 | -9.74% | 2,703,832 |
Delayed Quote London S.E., May 09, 2024 at 05:26 am EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.92% | 6.26M | |
-17.50% | 18.51B | |
-42.09% | 2.85B | |
+23.15% | 1.95B | |
+3.08% | 1.72B | |
+28.27% | 1.26B | |
-11.16% | 1.02B | |
-17.21% | 950M | |
+0.07% | 777M | |
-23.17% | 643M |
- Stock Market
- Equities
- EHP Stock